“Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s313, https://doi.org/10.25251/skin.8.supp.313.